Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more) Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more) Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Neurocrine Biosciences Inc NBIX

Healthcare Biotechnology
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:NBIX)

Neurocrine Biosciences Presented Baseline Data from the CAHtalyst(TM) Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024

PR Newswire 2 days ago

Neurocrine Biosciences Presents CAHtalyst(TM) Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

PR Newswire 7 days ago

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults

PR Newswire 7 days ago

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults

PR Newswire 8 days ago

Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference

PR Newswire 9 days ago

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst(TM) Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024

PR Newswire 9 days ago

Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring

PR Newswire 10 days ago

Neurocrine Biosciences Presented CAHtalyst(TM) Pediatric Study Baseline Characteristics and CAHtalog(TM) Registry Data at PES 2024

PR Newswire 13 days ago

Neurocrine Biosciences Reports First Quarter 2024 Financial Results

PR Newswire May 1, 2024
View More News ››

Opinion & Analysis (NDAQ:NBIX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:NBIX)

And Soros Buys In?

http://www.gurufocus.com/StockBuy.php?symbol=NBIX
scissors14 - June 29, 2006

Pfizer Rejects Indiplon

U.S. Equity News: AstraZeneca Cholesterol Drug Effective and Abbott Phase III Data Jun 26, 2006 (M2 PRESSWIRE via COMTEX News Network...
scissors14 - June 29, 2006

Clinical trails show

San Diego-based Neurocrine Biosciences (NASDAQ: NBIX) says clinical trials show its new drug can reduce the size of inoperable advanced...
SCCNewsServices - April 19, 2000
View more Bullboard ››

Bitget

Bitget

Bitget is a leading cryptocurrency exchange serving 20+ million users in 100+ countries and processing daily trading volume ...
View More »